Investors

2025 Second quarter announcement

We announced our second quarter 2025 results on Wednesday 30 July. Access our second quarter results and latest Annual Report below.

Q2 2025 results Annual Report 2024

Close video

We’re confident in our future

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Why invest in GSK?

Citi European Healthcare Conference, London

Access all speeches and presentations

17 June 2025

Tony Wood, Chief Scientific Officer, attended the Citi European Healthcare Conference in London on Tuesday, 17 June 2025.

Goldman Sachs Global Healthcare Conference

Access all speeches and presentations

09 June 2025

Kimberly Smith, Head of R&D at ViiV Healthcare, attended the Goldman Sachs Global Healthcare Conference in Miami on Monday, 9 June 2025.

NYSE Health Care Virtual Investor Access Day

Access all speeches and presentations

05 June 2025

David Redfern, President Corporate Development, attended the NYSE Health Care Virtual Investor Access Day on Thursday, 5 June 2025.

BNP Paribas Exane CEO Conference

Access all speeches and presentations

05 June 2025

Julie Brown, Chief Financial Officer, attended the BNP Paribas Exane CEO Conference in Paris on Thursday, 5 June 2025.

Goldman Sachs Biopharma Innovation Summit

Access all speeches and presentations

27 March 2025

David Redfern, President, Corporate Development, attended the Goldman Sachs Biopharma Innovation Summit in London on Thursday, 27 March 2025.

Shareholder information

GSK dividend

GSK share price

Share price tool

Detailed information on GSK's share price, including an interactive chart

Go to share price tool

Behind the science

Read our latest articles

‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘How do we improve trust in prevention? The answer lies closer to home than you might think’

‘We’re aiming to protect even more children’: Research starts on second-generation malaria vaccine to prevent most severe form of disease

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

Behind the science magazine

Investors

2025 Second quarter announcement

We’re confident in our future

Speeches and presentations

Citi European Healthcare Conference, London

Goldman Sachs Global Healthcare Conference

NYSE Health Care Virtual Investor Access Day

BNP Paribas Exane CEO Conference

Goldman Sachs Biopharma Innovation Summit

Shareholder information

GSK dividend

GSK share price

Share price tool

Read our latest articles

‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘How do we improve trust in prevention? The answer lies closer to home than you might think’

‘We’re aiming to protect even more children’: Research starts on second-generation malaria vaccine to prevent most severe form of disease

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

You might also like

Investors

2025 Second quarter announcement

We’re confident in our future

Stock exchange announcements

Quarterly results

Analyst consensus

Financial reports

Speeches and presentations

Citi European Healthcare Conference, London

Goldman Sachs Global Healthcare Conference

NYSE Health Care Virtual Investor Access Day

BNP Paribas Exane CEO Conference

Goldman Sachs Biopharma Innovation Summit

Shareholder information

GSK dividend

Dividend calculators (GBp/USD)

Dividend calendar

GSK share price

Share price tool

Read our latest articles

‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘How do we improve trust in prevention? The answer lies closer to home than you might think’

‘We’re aiming to protect even more children’: Research starts on second-generation malaria vaccine to prevent most severe form of disease

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

You might also like

Pipeline

Our leading scientists

Governance